Synergistic Abuse Deterrent Pharmaceutical Systems

Integrating abuse deterrent pharmaceutical compositions with AI, IoT, blockchain, and nanomaterials to create a more powerful system for preventing drug abuse and ensuring personalized drug delivery.

The original patent disclosed abuse deterrent pharmaceutical compositions that addressed opioid abuse. However, these compositions had limitations in tracking and controlling dosage, as well as ensuring personalized delivery. The new inventive concept addresses these limitations by synergistically combining the abuse deterrent pharmaceutical composition with distinct technologies to create a more robust system.

The new inventive concept comprises a synergistic combination of an abuse deterrent pharmaceutical composition and one or more of the following: AI-powered dosage tracking devices, blockchain-secured, IoT-enabled pharmaceutical compositions, pH-dependent solubility features, nanomaterial-based delivery systems, pH-modifying features, microchip-enabled tracking devices, and AI-powered genomic analysis tools. These components work together to monitor and control the release of the pharmaceutically active ingredient, track and verify dosage, and predict user response to the pharmaceutically active ingredient.

The new claims introduce a synergistic combination of distinct technologies that provides a more robust system for preventing drug abuse and ensuring personalized drug delivery. The integration of these technologies with the abuse deterrent pharmaceutical composition is new and non-obvious compared to the original patent.

Alternative embodiments may include integrating the abuse deterrent pharmaceutical composition with other technologies, such as machine learning algorithms, wearable devices, or cloud-based data analytics platforms. Variations may include using different types of nanomaterials, pH-modifying features, or genomic analysis tools.

The inventive concept has significant commercial potential in the pharmaceutical industry, particularly in the areas of opioid abuse prevention and personalized drug delivery. Target markets may include pharmaceutical companies, healthcare providers, and government agencies focused on addressing the opioid epidemic.